Reducing Lentiviral Vector Manufacturing Timelines with dbDNA™ Lentiviral vectors are essential for some of today’s most transformative cell and gene therapies, from CAR-T to modified stem cell treatments. But…
Read More
How AI Assisted Bioprocessing Can Transform Biotech Biotechnology is evolving, but some methods haven’t caught up. Slow experiments, costly materials, and outdated assumptions are holding back innovation. As demand…
Read More
Why Cell-Free DNA Is Replacing Plasmids in Next-Gen Genetic Medicine In the fast-moving world of genetic medicine, cell-free DNA production has the potential to significantly advance the industry by making…
Read More
How to Scale DNA Production Effectively to Meet the Needs of Genetic Medicines DNA is the blueprint of life, carrying the molecular instructions that tell every cell how to…
Read More
dbDNA™: The Future of AAV Production Recombinant adeno-associated virus (AAV) is one of the most promising delivery vehicles for genetic medicines, offering potential to treat a range of previously…
Read More
From Lab to Clinic: How z- dbDNA™ is Changing RNA Cell Therapy RNA is revolutionising cell therapy. Whether it's encoding genome-editing tools such as Cas9 to make precise DNA…
Read More
CRISPR HDR Breakthrough with mbDNA™: ssDNA Template Boosts Cell Viability & Scalability CRISPR has transformed our ability to edit genomes, enabling targeted insertions, deletions, and base corrections. Yet…
Read More
Touchlight’s robust and rapidly scalable manufacturing technology, offers a reliable and effective alternative to pDNA as a knock-in template for CRISPR and, thus, promises to advance non-viral gene therapy. Download…
Read More
As gene therapy accelerates, the demand for scalable viral vector manufacturing has never been greater. Yet traditional plasmid DNA (pDNA) remains a limiting factor, slowed by scalability challenges, bacterial contamination…
Read More
Here, we demonstrate that dbDNATM can be optimised for the manufacture of high titre LVV.
Read More
